Longitudinal Diary Data: Six Months Real-world Implementation of Affordable Companion Robots for Older People in Supported Living

被引:20
|
作者
Bradwell, Hannah L. [1 ]
Winnington, Rhona [2 ]
Thill, Serge [3 ]
Jones, Ray B. [1 ]
机构
[1] Univ Plymouth, Fac Hlth, Plymouth, Devon, England
[2] Auckland Univ Technol, Dept Nursing, Auckland, New Zealand
[3] Radbound Univ, Donders Ctr Cognit, Nijmegen, Netherlands
关键词
Companion robots; older people; wellbeing; DEMENTIA; SYMPTOMS; CARE;
D O I
10.1145/3371382.3378256
中图分类号
TP3 [计算技术、计算机技术];
学科分类号
0812 ;
摘要
Companion robots have potential for improving wellbeing within aged care, however literature focuses on shorter-term studies often using relatively expensive platforms, raising concerns around novelty effects and economic viability. Here, we report ecologically valid diary data from two supported living facilities for older people with dementia or learning difficulties. Both sites implemented Joy for All robot animals and maintained diaries for six months. Entries were analysed using thematic analysis. We found robot use increased over the six months, changing from short, structured sessions to mainly permanent availability. Thus previously reported concerns on novelty were not warranted. Both sites reported positive outcomes including reminiscence, improved communication and potential wellbeing benefits (reduced agitation/anxiety). Incidences of negative response included devices described as 'creepy.' Devices appeared sufficiently robust for prolonged daily use with multiple users. Overall, we provide insight into real-world implementation of affordable companion robots, and longitudinal development of use.
引用
收藏
页码:148 / 150
页数:3
相关论文
共 43 条
  • [31] Treatment Experienced People Living With HIV switching to DOR/3TC/TDF in Outpatient Setting: Real-World Data on Tolerability and Cost Savings From an Italian Multicenter Cohort
    Iannone, Valentina
    Ciccullo, Arturo
    Moschese, Davide
    Giacomelli, Andrea
    Fabbiani, Massimiliano
    Lagi, Filippo
    Papalini, Chiara
    De Vito, Andrea
    Cossu, Maria Vittoria
    Di Giambenedetto, Simona
    Borghetti, Alberto
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (02) : e10 - e11
  • [32] Age- and sex-specific 99th percentile upper reference limits for high-sensitivity cardiac troponin T in Chinese older people: Real-world data mining
    Zhang, Qian
    Chen, Huiyi
    Wang, Meng
    Lai, Huiying
    Liu, Wensong
    Wang, Lijuan
    Zhang, Jiaqi
    Li, Chuanbao
    Zhou, Weiyan
    CLINICAL BIOCHEMISTRY, 2024, 127
  • [33] Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
    Postel, N.
    Schneeweiss, S.
    Wyen, C.
    Schabaz, F.
    Degen, O.
    Weinberg, G.
    Sabranski, M.
    Ummard-Berger, K.
    Dymek, K.
    Westermayer, B.
    Scherzer, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 48 - 49
  • [34] Adverse event profiles of therapies that target the calcitonin gene-related peptide (CGRP) pathway, during the first six months after launch: A real-world data analysis using the FDA adverse events reporting system (FAERS)
    Silberstein, Stephen D.
    Reshef, Shoshana
    Cohen, Joshua M.
    Gandhi, Sanjay
    Seminerio, Michael
    Campos, Verena Ramirez
    Kessler, Yoel
    Thompson, Stephen
    Blumenfeld, Andrew
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 26 - 27
  • [35] Adverse Event Profiles of Therapies that Target the Calcitonin Gene-Related Peptide (CGRP) Pathway, During the First Six Months After Launch: A Real-world Data Analysis Using the FDA Adverse Events Reporting System (FAERS)
    Silberstein, Stephen D.
    Reshef, Shoshana
    Cohen, Joshua M.
    Gandhi, Sanjay
    Seminerio, Michael
    Campos, Verena Ramirez
    Kessler, Yoel
    Thompson, Stephen
    Blumenfeld, Andrew
    NEUROLOGY, 2020, 94 (15)
  • [36] Adverse Event Profiles of Therapies That Target the Calcitonin Gene-Related Peptide (CGRP) Pathway, During the First Six Months after Launch: A Real-World Data Analysis Using the FDA Adverse Events Reporting System (FAERS)
    Silberstein, Stephen D.
    Reshef, Shoshana
    Cohen, Joshua M.
    Gandhi, Sanjay
    Seminerio, Michael
    Campos, Verena Ramirez
    Kessler, Yoel
    Thompson, Stephen F.
    Blumenfeld, Andrew
    ANNALS OF NEUROLOGY, 2020, 88 : S153 - S153
  • [37] ADVERSE EVENT PROFILES OF THERAPIES THAT TARGET THE CALCITONIN GENE-RELATED PEPTIDE (CGRP) PATHWAY, DURING THE FIRST SIX MONTHS AFTER LAUNCH: A REAL-WORLD DATA ANALYSIS USING THE FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS)
    Silberstein, S. D.
    Reshef, S.
    Cohen, J. M.
    Gandhi, S.
    Seminerio, M.
    Ramirez-Campos, V
    Kessler, Y.
    Thompson, S. F.
    Blumenfeld, A.
    VALUE IN HEALTH, 2020, 23 : S634 - S634
  • [38] Real-world data on metabolic profile and renal function in a Latin American cohort of people living with HIV starting or switching to bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination: 48-week follow-up
    Cecchini, D. M.
    Mauas, R.
    Copertari, G.
    Brizuela, M.
    Bacelar, B.
    Castro, G.
    Diana Menendez, S.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 112 - 112
  • [39] Real-world data from the prospective, multicentre study on the use of dolutegravir-based regimens (DBRs) in ART-naive and experienced people living with HIV: 12-month results from the Russian TESLA study
    Kuznetsov, S.
    Minaeva, S.
    Sizova, N.
    Nagimova, F.
    Orlova-Morozova, E.
    Radzikhovskaya, M.
    Shevchenko, V.
    Maldonado, A.
    Jones, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 82 - 83
  • [40] 12-month outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Scholten, S.
    Noe, S.
    Wyen, C.
    Beer, D.
    Postel, N.
    Degen, O.
    Pauli, R.
    Hillenbrand, H.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2021, 22 : 111 - 112